Mandate

Vinge has advised Vicore Pharma in connection with a directed share issue of approximately SEK 125 million

November 13, 2019 Capital Markets and Public M&A

Vinge has advised Vicore Pharma, a Swedish rare disease company focused on interstitial lung diseases and related indications, in connection with a directed share issue whereby Vicore Pharma will receive approximately SEK 125 million in issue proceeds.

The subscription price was determined to SEK 16 per share through an accelerated book building process. The share issue was directed to a number of Swedish and international institutional investors. The main purpose of the share issue is to finance Vicore Pharma’s development of current and future product candidates. 
Vinge’s team consisted of Jesper Schönbeck, Nils Fredrik Dehlin and Stephanie Stiernstedt.

 

Related

Vinge has advised Gränges on the refinancing of its sustainability-linked credit facility

Vinge has advised Gränges AB (publ) (“Gränges”), a global leader in aluminium rolling and recycling in selected niches, on the refinancing of its sustainability-linked credit facility, which supports Gränges’ sustainability plan.
February 10, 2025

Vinge has advised Priveq Fund VII in connection with a sustainability-linked credit facility

Priveq Fund VII has entered into a credit facility agreement with Swedbank AB (publ) which will primarily be used to finance the fund’s investment activities. The credit facility is linked to certain of Priveq’s sustainability targets, which means that the interest rate on the credit facility will be adjusted up or down based on the performance of Priveq Fund VII's portfolio companies.
February 10, 2025

Vinge advised ReCarber in financing round

Vinge has advised ReCarber AB in its SEK 60 million financing round. The investors included Luminar Ventures, Spintop Ventures and Course Corrected.
February 10, 2025